Join VCs, academic innovators and biopharma executives to connect, collaborate and accelerate innovation at the forefront of drug R&D
Top decision-makers from across the biopharma ecosystem will convene in Chicago for the 2nd BioCentury Grand Rounds – U.S., at the intersection of research, investment and drug development. Designed to drive practical progress in R&D, the conference connects academic innovators with biopharma executives and early-stage investors who are building the next wave of biotech breakthroughs.
Taking place June 4 – 6 at the Four Seasons Hotel Chicago, the program will address critical bottlenecks in three themes:
- Disease biology
- Therapeutic modalities
- Enabling technologies
Featured sessions include a plenary with Marty Burke, Professor of Chemical Innovation at the University of Illinois Urbana-Champaign, and a fireside chat with Jonathon Sedgwick, SVP and Global Head of Discovery Research at AbbVie. In a special Horizon session, Luciana Borio, Venture Partner at ARCH Ventures, will lead a panel on the future of research funding. View the full agenda.
Speakers include R&D, investment and academic leaders from AUTM, Biogen, Chan Zuckerberg Biohub Chicago, Daiichi Sankyo, Deerfield Management, Eli Lilly, Genmab, Johnson & Johnson Innovation, Merck & Co., Northwestern University, Novartis Venture Fund, Takeda, The University of Chicago and many other leaders in the industry.
“At this complex and politically fraught moment, bringing industry and academia together to enable the future of translational research is more critical than ever,” said Simone Fishburn, VP & Editor in Chief of BioCentury. “BioCentury continues its 30-year tradition of fostering the future of medicine, bringing innovators and investors to delve into the science that can write the next stories in biotech.”
“We are hugely pleased the Chicago Biomedical Consortium and their Midwest colleagues have joined the Grand Rounds community,” said BioCentury Co-Founder and CEO David Flores. “This important biomedical ecosystem will be a foundational link in the global network BioCentury is building to collectively identify solutions for translating great science into transformational cures.”
Flores added: “The Grand Rounds network, begun last year with our launch partners Vanderbilt University and Life Science Tennessee, will grow further with our first Grand Rounds - Europe meeting in the U.K. in September, led by Cambridge University Health Partners, Cambridge Innovation Capital and AstraZeneca.”
The importance of Grand Rounds in Chicago is demonstrated by its collaborators. Insights Partner McKinsey & Company is joined by Founding Investors ARCH Venture Partners, Iaso Ventures, Lightspeed Venture Partners, MPM BioImpact, Third Rock Ventures and Xontogeny; and Sponsors Chan Zuckerberg Biohub Chicago, Collaborative Drug Discovery, inThought Research and Xentria.
Regional Hosts advancing innovation in the Midwest include Chicago Biomedical Consortium, iBIO, Northwestern Memorial Healthcare, Northwestern University, P33, Portal Innovations, The University of Chicago, University of Illinois Chicago, and the University of Illinois Urbana-Champaign.
Learn more and register at www.biocenturygrandroundsus.com or email Brian Denker at conferences@biocentury.com.
Share your science as a Presenting Company or poster presenter. Become a Sponsor.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250513990232/en/
BioCentury is bringing together VCs, biopharma R&D decision-makers and academic innovators to discuss critical bottlenecks in the translation of scientific discoveries into the next wave of biotech breakthroughs. #BioCenturyGrandRounds
Contacts
Brian Denker
conferences@biocentury.com
